Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,863 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 319 · Balance 87,863 F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 319 | $12.21 | $3,894.99 |
DisclosureSEC source: 0001193125-26-412434 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,863 F1 · price: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 00:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 222 | $17.84 | $3,960.48 |
DisclosureSEC source: 0001193125-26-296614 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,544 F1 · price: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionStock Options (right to buy) · Derivative | 500 | $10.00 Strike: $10.00 | $5,000.00 |
DisclosureSEC source: 0001193125-26-261835 · ownership.xml · derivative · entry 3 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2026-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This option was previously reported as covering 20,000 shares at an exercise price of $0.25 per share, but was adjusted to reflect the stock split that occurred on July 27, 2016. F1 · derivative.underlying_shares: This option was previously reported as covering 20,000 shares at an exercise price of $0.25 per share, but was adjusted to reflect the stock split that occurred on July 27, 2016. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 376 | $13.30 | $5,000.80 |
DisclosureSEC source: 0001193125-26-261835 · ownership.xml · nonDerivative · entry 2 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,322 Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 500 | $10.00 | $5,000.00 |
DisclosureSEC source: 0001193125-26-261835 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 5,415 | $12.17 | $65,900.55 |
DisclosureSEC source: 0001193125-26-253602 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,198 F1 · kind: This sale of shares was made to cover the tax liability incident to the vesting of 12,417 shares on May 19, 2026 under a restricted stock unit granted to the director on May 22, 2025. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $12.04 to $12.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 12,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-239441 · ownership.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,820 Underlying: Common Stock · 12,820 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234570 · ownership.xml · derivative · entry 2 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234570 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 18:49 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 442 | $9.10 | $4,022.20 |
DisclosureSEC source: 0001193125-26-139777 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,196 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:46 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 884 | $13.68 | $12,093.12 |
DisclosureSEC source: 0001193125-26-002935 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,754 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2025. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 23:04 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 555 | $21.79 | $12,093.45 |
DisclosureSEC source: 0001193125-25-228824 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,870 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:03 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 934 | $11.94 | $11,151.96 |
DisclosureSEC source: 0000950170-25-093154 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,315 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2025. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 23:26 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 10,000 | $13.28 | $132,800.00 |
DisclosureSEC source: 0000950170-25-085714 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,381 F1 · kind: This sale of shares was made to cover the tax liability incident to the vesting of 21,903 shares on May 16, 2025 under a restricted stock unit granted to the director on May 16, 2024. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $13.27 to $13.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 22, 2025 Filed May 23, 2025 21:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 12,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077157 · ownership.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,417 Underlying: Common Stock · 12,417 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:34 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074420 · ownership.xml · derivative · entry 2 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:34 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074420 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:22 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 938 | $11.89 | $11,152.82 |
DisclosureSEC source: 0000950170-25-049820 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,288 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:51 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 725 | $15.38 | $11,150.50 |
DisclosureSEC source: 0000950170-25-001304 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,350 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2024. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:22 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 995 | $11.21 | $11,153.95 |
DisclosureSEC source: 0001285550-24-000114 · wk-form4_1727900554.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,625 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2024. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 21:19 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 2,069 | $5.39 | $11,151.91 |
DisclosureSEC source: 0001285550-24-000084 · wk-form4_1719955190.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,630 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 28, 2024. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:23 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 21,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000067 · wk-form4_1715977372.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,093 Underlying: Common Stock · 21,093 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:16 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000053 · wk-form4_1715779003.xml · derivative · entry 2 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,153 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:16 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 17,153 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001285550-24-000053 · wk-form4_1715779003.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:41 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,640 | $6.80 | $11,152.00 |
DisclosureSEC source: 0001285550-24-000040 · wk-form4_1712090489.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,408 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 28, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:57 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,643 | $6.79 | $11,155.97 |
DisclosureSEC source: 0001285550-24-000006 · wk-form4_1704301034.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,768 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 29, 2023. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 16:41 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 2,226 | $5.01 | $11,152.26 |
DisclosureSEC source: 0001285550-23-000106 · wf-form4_169635129528956.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,125 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:46 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,540 | $7.24 | $11,149.60 |
DisclosureSEC source: 0001285550-23-000079 · wf-form4_168859356652618.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,899 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2023. Read SEC document |
| May 25, 2023 Filed May 26, 2023 18:11 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-23-000063 · wf-form4_168512468308665.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,153 Underlying: Common Stock · 17,153 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:57 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,321 | $8.44 | $11,149.24 |
DisclosureSEC source: 0001285550-23-000039 · wf-form4_168064184614156.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,359 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 22:59 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,399 | $7.97 | $11,150.03 |
DisclosureSEC source: 0001285550-23-000008 · wf-form4_167287314329964.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,038 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $7.97 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending December 30, 2022. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:18 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,094 | $10.19 | $11,147.86 |
DisclosureSEC source: 0001285550-22-000064 · wf-form4_166492186503764.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,639 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $10.19 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending September 30, 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 18:37 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 883 | $12.63 | $11,152.29 |
DisclosureSEC source: 0001285550-22-000030 · wf-form4_165713266139806.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,545 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $12.63 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending June 30, 2022. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:27 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,179 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0001420506-22-001136 · doc4_1014.xml · derivative · entry 2 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,179 Underlying: Common Stock · 6,179 shares Expires 2032-05-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:27 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 9,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001420506-22-001136 · doc4_1014.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,662 F1 · price: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:10 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,120 | $9.96 | $11,155.20 |
DisclosureSEC source: 0001171520-22-000239 · eps10158.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,393 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $9.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2022. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 12:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 644 | $11.54 | $7,431.76 |
DisclosureSEC source: 0001171520-22-000014 · doc4_989.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,273 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $11.54 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2021. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:13 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 414 | $17.92 | $7,418.88 |
DisclosureSEC source: 0001420506-21-001359 · doc4_969.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,629 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $17.92 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended October 1, 2021. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 291 | $20.26 | $5,895.66 |
DisclosureSEC source: 0001420506-21-000844 · doc4_936.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,215 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $20.26 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2021. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:36 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,006 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001171520-21-000264 · ownership.xml · derivative · entry 2 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,006 Underlying: Common Stock · 6,006 shares Expires 2031-06-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:36 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001171520-21-000264 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,924 F1 · shares: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:06 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 306 | $19.57 | $5,988.42 |
DisclosureSEC source: 0001420506-21-000379 · doc4_921.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,921 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 23:36 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 399 | $15.00 | $5,985.00 |
DisclosureSEC source: 0001420506-21-000009 · doc4_893.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,615 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 22:09 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,051 | $5.71 | $6,001.21 |
DisclosureSEC source: 0001420506-20-001034 · doc4_860.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,216 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 17:31 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,687 | $3.55 | $5,988.85 |
DisclosureSEC source: 0001171520-20-000287 · doc4_815.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,165 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.55 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2020. Read SEC document |
| June 03, 2020 Filed Jun 17, 2020 20:12 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001420506-20-000693 · doc4_809.xml · derivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2021 annual meeting of stockholders. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:08 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,680 | $3.57 | $5,997.60 |
DisclosureSEC source: 0001420506-20-000353 · doc4_796.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,478 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2020. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 22:04 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 605 | $4.96 | $3,000.80 |
DisclosureSEC source: 0001420506-20-000008 · doc4_781.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,798 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:11 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 582 | $5.15 | $2,997.30 |
DisclosureSEC source: 0001534424-19-000273 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,193 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2019. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:11 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 947 | $3.17 | $3,001.99 |
DisclosureSEC source: 0001534424-19-000199 · ownership.xml · nonDerivative · entry 1 Richards Timothy T. · CIK 0001601831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,611 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.17 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 28, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.